Medtronic Has Agreed To Acquire EOFlow, Manufacturer Of The EOPatch Device, A Tubeless, Wearable, And Fully Disposable Insulin Delivery Device, For $738M
Portfolio Pulse from Benzinga Newsdesk
Medtronic has agreed to acquire EOFlow, a manufacturer of the EOPatch device, a tubeless, wearable, and fully disposable insulin delivery device, for $738 million.
May 25, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's acquisition of EOFlow for $738M could strengthen its position in the insulin delivery device market.
The acquisition of EOFlow and its EOPatch device will likely enhance Medtronic's product portfolio in the insulin delivery device market. This could lead to increased market share and revenue, positively impacting Medtronic's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100